About Steve Reitmeister

Steve Reitmeister is the CEO of StockNews.com, bringing 40 years of experience to help individual investors find outperformance. For the better part of the past two decades he was the Editor-in-Chief of Zacks.com where millions of investors enjoyed his timely market insights. His commentary has also been featured on other leading investment websites including Yahoo Finance, SeekingAlpha, CNNMoney and MarketWatch. Steve has an MBA from DePaul University and B.A. in Economics from the University of Wisconsin (Go Badgers!).

Steve is also the Editor of the Reitmeister Total Return portfolio service. This is where he puts those 40 years of experience to work for you in selecting the best trades for the current market environment. See the Reitmeister Total Return portfolio.


Recent Articles By Steve Reitmeister

: SNY |  News, Ratings, and Charts

Top 10 Growth & Income Stocks to Weather the Storm

Sanofi (SNY) is one of 10 growth & income stocks combining the right ingredients to outperform during this volatile stretch for the market. Discover all the criteria helping to produce this list of 10 quality stocks.
: GM |  News, Ratings, and Charts

Top 16 Value Stocks to Start September

General Motors joins a group of 16 select value stocks with more than 30% upside to fair value. Discover the rest of the criteria used to unearth these rare value stocks with impressive fundamental strength.
: DBX |  News, Ratings, and Charts

Stock of the Week: Dropbox (DBX)

Dropbox is my Stock of the Week for packing a 1-2 punch of strong growth and exceptional value...like 70% upside to fair value targets. Read on for more.
: SPY |  News, Ratings, and Charts

How Scary is September for Stocks?

The outlook for the market and index funds like SPY are haunted by events in previous Septembers. Let's discuss the fact and fiction of those past results and what it tells us about our portfolio strategy for this September.
: EOG |  News, Ratings, and Charts

70 Dogs With Fleas (aka Strong Sell Stocks)

EOG Resources is just one of 70 stocks recently downgraded to Strong Sell. See what is wrong with these stocks and links to resources to find better stocks to buy now.
: ABT |  News, Ratings, and Charts

78 Spirited Stocks Upgraded to Strong Buy

Abbott Laboratories is one of 78 freshly minted Strong Buy stocks. That is an important medal of honor to achieve when the market clouds are this stormy. Discover what makes these 78 stocks so special below.
: VZ |  News, Ratings, and Charts

Stock of the Week: Verizon Communications (VZ)

Verizon is one of the most recent additions to the Reitmeister Total Return portfolio. See how well it stacks up on growth, value, income and momentum attributes. More importantly, why it is the right stock to buy at this volatile time for the market.
: SPY |  News, Ratings, and Charts

Investors: How Low Will Stocks Go?

SPY and the rest of the index ETFs are likely in a world of hurt as the market looks poised to head lower...potentially much lower. Read on to appreciate the catalysts at play and your best investing strategy at this time.
: OAK |  News, Ratings, and Charts

8 Elite Income Stocks with 8%+ Dividend Yield

Oaktree Capital Group pays a 8% dividend yield with a history of increasing that payout by 11% a year. And that is the least attractive stock on this list of 8 elite income stocks. Read on for more.
: CPRX |  News, Ratings, and Charts

7 Stocks to Get Your Heart Racing!

Catalyst Pharma is trading 51% under its fair value target...and that is the most boring stock on this list. Read on to discover the full list of 7 with up to 155% upside.
Page generated in 1.2729 seconds.